NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free LGND Stock Alerts $86.06 +1.04 (+1.22%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$85.17▼$86.9050-Day Range$68.53▼$87.2852-Week Range$49.24▼$94.57Volume100,217 shsAverage Volume165,627 shsMarket Capitalization$1.55 billionP/E Ratio16.65Dividend YieldN/APrice Target$116.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ligand Pharmaceuticals alerts: Email Address Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.2% Upside$116.33 Price TargetShort InterestHealthy4.42% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.23Based on 17 Articles This WeekInsider TradingSelling Shares$2.30 M Sold Last QuarterProj. Earnings Growth16.72%From $3.41 to $3.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.91 out of 5 starsMedical Sector17th out of 920 stocksPharmaceutical Preparations Industry5th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Ligand Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.42% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 3.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 2.4 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,303,916.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 16.72% in the coming year, from $3.41 to $3.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 16.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 16.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 106.31.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesMay 18 at 10:19 AM | insidertrades.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells 934 Shares of StockMay 16 at 1:13 PM | insidertrades.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells 3,440 Shares of StockMay 14, 2024 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 10,000 SharesMay 19 at 5:46 AM | americanbankingnews.comOctavio Espinoza Sells 5,156 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 19 at 5:46 AM | americanbankingnews.comOctavio Espinoza Sells 5,873 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 17 at 8:10 PM | investing.comLigand Pharmaceuticals director Nancy Gray sells shares worth over $77kMay 17 at 8:10 PM | investing.comLigand Pharmaceuticals CFO sells over $1.1 million in stockMay 17 at 6:36 AM | americanbankingnews.comMatthew E. Korenberg Sells 3,440 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 16 at 10:27 AM | finance.yahoo.comInsider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...May 14, 2024 | markets.businessinsider.comLigand Moves to Strong Buy: Rationale Behind the UpgradeMay 12, 2024 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Rating Reiterated by HC WainwrightMay 9, 2024 | finance.yahoo.comLigand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)May 9, 2024 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Trading 7.3% Higher Following Strong EarningsMay 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | finance.yahoo.comQ1 2024 Agenus Inc Earnings CallMay 7, 2024 | investorplace.comLGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | markets.businessinsider.comLigand Pharmaceuticals Inc Q1 Profit Increases, beats estimatesMay 7, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Mixed Q1 2024 Results: Misses Revenue Estimates but ...May 7, 2024 | seekingalpha.comLigand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | businesswire.comLigand Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comLigand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt.May 7, 2024 | businesswire.comLigand and Agenus Enter Into $100 Million Royalty Financing AgreementApril 23, 2024 | businesswire.comLigand to Report First Quarter 2024 Financial Results on May 7, 2024April 17, 2024 | finance.yahoo.comWall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should KnowSee More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/19/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees58Year FoundedN/APrice Target and Rating Average Stock Price Target$116.33 High Stock Price Target$144.00 Low Stock Price Target$95.00 Potential Upside/Downside+35.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$5.17 Trailing P/E Ratio16.65 Forward P/E Ratio25.24 P/E GrowthN/ANet Income$52.15 million Net Margins79.30% Pretax Margin102.75% Return on Equity8.52% Return on Assets7.50% Debt Debt-to-Equity RatioN/A Current Ratio20.70 Quick Ratio19.51 Sales & Book Value Annual Sales$131.31 million Price / Sales11.80 Cash Flow$5.00 per share Price / Cash Flow17.20 Book Value$44.81 per share Price / Book1.92Miscellaneous Outstanding Shares18,000,000Free Float16,128,000Market Cap$1.55 billion OptionableOptionable Beta1.01 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Comp: $831.77kMr. Octavio Espinoza (Age 53)Chief Financial Officer Comp: $613.59kMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Comp: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXMannKindNASDAQ:MNKDIronwood PharmaceuticalsNASDAQ:IRWDInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsCastleark Management LLCSold 789 shares on 5/17/2024Ownership: 0.344%Octavio EspinozaSold 5,156 sharesTotal: $446,818.96 ($86.66/share)Comerica BankSold 740 shares on 5/17/2024Ownership: 0.044%Walleye Trading LLCSold 3,300 shares on 5/17/2024Ownership: 0.000%California State Teachers Retirement SystemSold 921 shares on 5/16/2024Ownership: 0.092%View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price targets for Ligand Pharmaceuticals' stock. Their LGND share price targets range from $95.00 to $144.00. On average, they predict the company's share price to reach $116.33 in the next twelve months. This suggests a possible upside of 35.2% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2024? Ligand Pharmaceuticals' stock was trading at $71.42 at the beginning of 2024. Since then, LGND stock has increased by 20.5% and is now trading at $86.06. View the best growth stocks for 2024 here. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its earnings results on Tuesday, May, 7th. The biotechnology company reported $3.84 EPS for the quarter, beating analysts' consensus estimates of $0.83 by $3.01. The biotechnology company had revenue of $30.90 million for the quarter, compared to analysts' expectations of $27.92 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 8.52% and a net margin of 79.30%. The firm's quarterly revenue was down 29.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.96 EPS. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Tema Global Royalties ETF (ROYA), Virtus LifeSci Biotech Products ETF (BBP), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Franklin Genomic Advancements ETF (HELX). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of 4.250-4.750 for the period, compared to the consensus EPS estimate of 4.440. The company issued revenue guidance of $130.0 million-$142.0 million, compared to the consensus revenue estimate of $137.7 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.64%), Janus Henderson Group PLC (5.60%), Villere ST Denis J & Co. LLC (2.77%), Rice Hall James & Associates LLC (1.58%), Ashford Capital Management Inc. (1.09%) and William Blair Investment Management LLC (1.07%). Insiders that own company stock include Andrew Reardon, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Nancy Ryan Gray, Octavio Espinoza, Stephen L Sabba and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGND) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.